Breast tomosynthesis may be a work-in-progress in the RSNA exhibit halls, but researchers are already considering ways to incorporate computer-assisted detection algorithms to improve its efficacy.
Breast tomosynthesis may be a work-in-progress in the RSNA exhibit halls, but researchers are already considering ways to incorporate computer-assisted detection algorithms to improve its efficacy.
Researchers from the University of Chicago and the University of Michigan presented papers Tuesday morning that evaluated several techniques for reconstructing suspected tumors from the multiple slices of tomographic acquisition or from the compiled volume data set. Both groups worked with the GE Digital Breast Tomosynthesis prototype developed by Dr. Daniel Kopans at Massachusetts General Hospital.
The Michigan researchers produced an area of 0.87 under the ROC curve with 80% sensitivity and two false positives per case, using a set of synthesized data. Looking only at projection views, the area under the ROC curve dropped to 0.82. Both were based on 26 cases with 23 masses, including 13 malignancies.
"We achieved fewer false positives with 3D views than with 2D, and the information fusion is more effective," said lead researcher Heang-Ping Chan, Ph.D.
Chicago researchers evaluated only projection views. A standard tomosynthesis scan involves 11 low-dose conebeam projections through the breast at 5-degree angles spread over an arc. The projections intersect with each other at various points and allow the software to confirm areas of suspected masses from more than one angle. For the Chicago trial, any region that was intersected by six or more projections was considered a positive finding. Among 21 cases of confirmed breast masses, the team achieved a sensitivity of 86%, but with six false positives per case.
In addition to projection views and reconstructed volumes, CAD could also be developed to look for suspicious findings across the 50 to 80 reconstructed image slices that could be produced for each set of breast data, the authors said.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.